News & Events
Psifas Initiative: Advancing Precision Medicine Through Israel's National Genomic Research Infrastructure
Tuesday,21 Oct 2025
Yesterday, Prof. Gabi Barbash, CEO of the Psifas Initiative, gave a lecture at the Faculty of Medicine at the Technion.
During the talk, Prof. Barbash presented Psifas - Israel’s national initiative that has established a cutting-edge infrastructure for medical and genomic research based on clinical and genomic data from approximately 60,000 volunteers across the country.
Through the infrastructure developed within the Psifas Initiative, researchers from healthcare, academia, and industry - in Israel and around the world - can conduct groundbreaking studies that advance the field of precision medicine.
Prof. Barbash discussed the Israeli Reference Genome Study (IRGS), ongoing prospective studies conducted through the Psifas Initiative, and the mapping of actionable genes - clinically significant genetic findings collected within Psifas that can support early detection and prevention of disease.
For more information about the initiative and research proposal submissions, see here -
https://partnership.psifas.org.il/
IRCF Grant for Innovative Technological Advance 2025
Monday,21 Jul 2025
We are happy to announced that our application entitled: “Development of Olink Reveal Technology in Multidisciplinary Core Facilities ” has been selected for funding through the 2025 IRCF Grant for Innovative Technological Advances. This is a collaboration between ATGC, Technion Smoler Proteomics Center, and Tel Aviv University Single Cell Genomics Core.
Olink Reveal is an advanced proteomics platform designed for high-throughput, targeted protein quantification with exceptional sensitivity and specificity. It uses dual antibody recognition paired with DNA barcoding and next-generation sequencing (NGS) to detect over 1,000 human proteins across diverse biological pathways. It is cost-effective, user-friendly, and suited for high-throughput clinical studies, with minimal sample input and simple preparation.
Here we suggest implementing Olink's technology and compare the results to MS-based proteomics in detecting early plasma biomarkers in patients’ samples from diverse clinical questions.
Liat
2025 ATGC Subsidy Program Announced for Technion Researchers
Wednesday, 2 April 2025
Following two successful years that enabled many of you to conduct cutting-edge genomic experiments in-house, we’re excited to share that RTICC will continue to support ATGC project subsidies through 2025.
Eligible applicants include:
-
Technion researchers with an active MOSAD-funded project
-
Researchers supported by a Rappaport Institute budget
-
New Technion faculty (joined within the last five years) with a procurement budget
-
Physician-researchers affiliated with Technion medical center
As in previous years, subsidies will cover 40% of basic applications and 70% of advanced applications, as detailed in the table below. Please provide your reimbursement budget at 2070. Once processed, the refund will appear under expenses category 600400 – technical assistance refund.
| Basic Applications (40%) | Advanced Application (70%) |
| RNA-seq | scRNA-seq |
| DNA-seq | scRNA-seq + immune cell profiling |
| ChIP-seq | snATAC-seq |
| Cut&run | scMultiomics |
| Amplicon-seq | Spatial transcriptomics- VisiumHD |
| 16S / 18S | Spatial transcriptomics- CosMx |
| RRBS | DNA-seq long-reads |
| miRNA-seq | |
| Exome | |
| NGS runs |
📌 Important: If you have worked with us between January 2025 and today, you're eligible to submit a retroactive request. We encourage you to do so promptly so that reimbursements can be processed right after Passover.
👉 Submit Your Subsidy Request Here
For any questions, feel free to reach out.
— Liat
